The problem
Biological threats, natural or AI-engineered, emerge faster than agencies can identify and counter them
What they do
AI platform that characterizes pathogens and helps design medical countermeasures for biodefense
Traction Early clients include US DoD and Los Alamos National Lab; no revenue disclosed
Hiring trend
- Open roles
- 8
- Ops roles
- 3
- Headcount
- ~17
~17 staff (LinkedIn), 'growing substantially'; open roles flat at 8 since Aug
Hiring in
- New York
- San Francisco
Latest news
Sep 2026
Published Grove brief: Bundibugyo ebolavirus outbreak characterized within five hours ↗Funding
- Last round
- $30M
- Stage
- Seed
- Date
- Oct 2025
Led by OpenAI Startup Fund, Lux Capital, Founders Fund
- Hiring+18 open roles on the live job board (3–9 roles = +1)
- Funding recency+1Seed · $30M, Oct 2025 (12 months ago): 6–12 months = +1
- Traction+0.75Some growth: Early clients include US DoD and Los Alamos National Lab; no revenue disclosed
- Red flags0None found in the last 24 months
- Total2.751 + 1 + 0.75 − 0 = 2.75 → Warm-up
Seed rule: seed-stage without strong traction starts in Warm-up whatever the score (Steady by score alone).
Distance (Unproven) is a separate read on how long the lead can last. It doesn't change the score.
Distance
Unproven · edge: hard to leave
A seed-stage company with a handful of government and lab clients; too early to judge staying power.
Sources: Forbes NBDS 2026 (via Forbes LinkedIn): clients incl. DoD and Los Alamos ↗ · PR Newswire, Oct 2025: $30M seed ↗
Last checked Oct 25, 2026